药物和其他医疗产品的绩效风险分担安排34.ppt

Conclusions Performance-based agreements are in line with healthcare trends They are intrinsically appealing Align incentives toward realized value Substantial barriers to implementation that will limit both the short-term and long-term impact Especially in the US. They will not apply to all medical products, but rather to a select group where the payer and manufacturer can find common ground Key principles for implementation of Patient Access Schemes in the UK are an indication of continued interest Fad or a trend? Stay tuned—yet to be determined. Thanks! lgarrisn@uw.edu 待情绪稍微冷静后，阿元才略带平